Multicomponent therapeutics for networked systems
The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Therapeutic regimens that comprise more than one active ingredient are commonly used in clinical medicine. Despite this, most drug discovery efforts search for drugs that are composed of a single chemical entity. A focus in the early drug discovery process on identifying and optimizing the activity of combinations of molecules can result in the identification of more effective drug regimens. A systems perspective facilitates an understanding of the mechanism of action of such drug combinations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“combinations of chemical agents (or manipulations such as those of transcription factors that affect multiple steps in a pathway [1906] or modulation of multiple gene products [2311], or both [2312,2313]) will be far more efficacious, for instance in modulating iron-catalysed oxidative stress and its sequelae, than will be the use of 'magic bullet' single agents.”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1705]
Citations
Cites
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“There have been attempts to systematize a set of principles that can account for combination drugs that exist toda”
BackgroundLessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Systems biology: a brief overview
Kitano, H. (2002) · Science · doi:10.1126/science.1069492 · Cited by 4,265 · cited 1×
“Systems biology is the large-scale study of the functional and physical relationships between the molecules that make up lif”
BackgroundBlume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Transcriptional Regulatory Networks in Saccharomyces cerevisiae
Lee, T. I., Rinaldi, N. J., Robert, F., Odom, D. T., Bar-Joseph, Z., Gerber, G. K., Hannett, N. M., Harbison, C. T., Thompson, C. M., Simon, I., et al. (2002) · Science · doi:10.1126/science.1075090 · Cited by 2,956
THE TOXICITY OF POISONS APPLIED JOINTLY1
BLISS, C. I. (1939) · Annals of Applied Biology · doi:10.1111/j.1744-7348.1939.tb06990.x · Cited by 2,419 · cited 1×
“Numerous researchers have attempted to provide an unambiguous framework for the calculation of additive effects between compounds; these approaches are reviewed comprehensively elsewher”
BackgroundSystematic Genetic Analysis with Ordered Arrays of Yeast Deletion Mutants
Tong, A. H. Y., Evangelista, M., Parsons, A. B., Xu, H., Bader, G. D., Pagé, N., Robinson, M., Raghibizadeh, S., Hogue, C. W. V., Bussey, H., et al. (2001) · Science · doi:10.1126/science.1065810 · Cited by 2,138
A N EW A PPROACH TO D ECODING L IFE : Systems Biology
Ideker, T., Galitski, T., & Hood, L. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.343 · Cited by 1,664 · cited 1×
“Systems biology is the large-scale study of the functional and physical relationships between the molecules that make up lif”
BackgroundDolma, S., Lessnick, S. L., Hahn, W. C., & Stockwell, B. R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00050-3 · Cited by 1,446
Self-citation
Research works printed but not linked: 2
- Ehrlich, P. Chemotherapeutics: scientific principles, methods and results. Lancet 2, 445–451 (1913).
- Albert, A. Selective Toxicity (Methuen & Co., London, 1968).
Cited by
Items 101–200 of 799
Targeting cell signaling pathways for drug discovery: An old lock needs a new key
Aggarwal, B. B., Sethi, G., Baladandayuthapani, V., Krishnan, S., & Shishodia, S. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21500 · Cited by 155
“Indeed, drug combinations that reach multiple targets simultaneously are better at controlling complex disease systems, less prone to drug resistance, and the standard of care in many important therapeutic areas [Keith et al., 2005].”
BackgroundInfluentialSymbiosis of chemometrics and metabolomics: past, present, and future
van der Greef, J., & Smilde, A. K. (2005) · Journal of Chemometrics · doi:10.1002/cem.941 · Cited by 136
“In pharmaceutical research for the same reason a clear trend is observed towards combination drugs for that reason with additional economical drivers [10–12].”
BackgroundChemProt-3.0: a global chemical biology diseases mapping
Kringelum, J., Kjaerulff, S. K., Brunak, S., Lund, O., Oprea, T. I., & Taboureau, O. (2016) · Database · doi:10.1093/database/bav123 · Cited by 138
“…amounts of data are generated and accumulated via new experimental technologies such as transcriptomic, proteomics and genomics (through next-generation sequencing), drug action can be explored across multiple scale of complexity, from molecular and cellular to tissue and organism levels (9– 11).”
Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer’s Disease
Rossi, M., Freschi, M., Nascente, L. D. C., Salerno, A., Teixeira, S. D. M. V., Nachon, F., Chantegreil, F., Soukup, O., Prchal, L., Malaguti, M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00048 · Cited by 147
PubChem as a Source of Polypharmacology
Chen, B., Wild, D., & Guha, R. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci9001876 · Cited by 140
A multiplexed microfluidic platform for rapid antibiotic susceptibility testing
Mohan, R., Mukherjee, A., Sevgen, S. E., Sanpitakseree, C., Lee, J., Schroeder, C. M., & Kenis, P. J. A. (2013) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2013.04.046 · Cited by 152
“The development of novel antimicrobials has lagged in pace relative to the rapid emergence of microbial drug resistance against several existing antibiotics (Keith et al., 2005).”
BackgroundNetwork-based drug discovery by integrating systems biology and computational technologies
Leung, E. L., Cao, Z., Jiang, Z., Zhou, H., & Liu, L. (2012) · Briefings in Bioinformatics · doi:10.1093/bib/bbs043 · Cited by 152
“With such a combination, optimum anti-bacterial synergy has been successfully produced [9].”
BackgroundSynergistic and Antagonistic Drug Combinations Depend on Network Topology
Yin, N., Ma, W., Pei, J., Ouyang, Q., Tang, C., & Lai, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093960 · Cited by 139
“Drug combinations have been envisaged by many to be a promising approach to treat complex diseases such as cancer, inflammation and type 2 diabetes [1–3].”
BackgroundOne‐compound‐multiple‐targets strategy to combat Alzheimer's disease
Zhang, H.-Y. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.09.006 · Cited by 138
“One is called multicomponent therapeutic strategy, which incorporates two or more active ingredients in one drug [2].”
BackgroundMultipotent antioxidants: from screening to design
Zhang, H., Yang, D., & Tang, G.-Y. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.06.007 · Cited by 137
Genome-environment interactions that modulate aging: powerful targets for drug discovery
de Magalhães, J. P., Wuttke, D., Wood, S. H., Plank, M., & Vora, C. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.004499 · Cited by 136
“Current progress in genomics, high-throughput methods, informatics, and systems biology should help to develop network approaches that test target combinations resulting in the emerging paradigm of network pharmacology (Keith et al., 2005; Hopkins, 2008).”
BackgroundTargeting non-malignant disorders with tyrosine kinase inhibitors
Grimminger, F., SCHERMULY, R. T., & Ghofrani, H. A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3297 · Cited by 143
Combinatorial drug discovery in nanoliter droplets
Kulesa, A. B., Kehe, J., Hurtado, J. E., Tawde, P., & Blainey, P. C. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802233115 · Cited by 143
Solomon, V. R., Hu, C., & Lee, H. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.01.001 · Cited by 135
Machine learning methods, databases and tools for drug combination prediction
Wu, L., Wen, Y., Leng, D., Zhang, Q., Dai, C., Wang, Z., Liu, Z., Yan, B., Zhang, Y., Wang, J., et al. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbab355 · Cited by 126
“There are many studies comparing Bliss with Loewe models [43, 45, 48–51].”
BackgroundResultWang, X., Sun, H. J., Zhang, A., Jiao, G., Sun, W., & Yuan, Y. (2011) · The Analyst · doi:10.1039/c1an15752c · Cited by 132
Mechanism-independent method for predicting response to multidrug combinations in bacteria
Wood, K., Nishida, S., Sontag, E. D., & Cluzel, P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201281109 · Cited by 135
Smart Nanoscale Drug Delivery Platforms from Stimuli-Responsive Polymers and Liposomes
Lee, S., & Nguyen, S. T. (2013) · Macromolecules · doi:10.1021/ma401529w · Cited by 134
Neoclassic Drug Discovery: The Case for Lead Generation Using Phenotypic and Functional Approaches
Lee, J. A., & Berg, E. L. (2013) · SLAS Discovery · doi:10.1177/1087057113506118 · Cited by 126
Rotili, D., Tomassi, S., Conte, M., Benedetti, R., Tortorici, M., Ciossani, G., Valente, S., Marrocco, B., Labella, D., Novellino, E., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4012802 · Cited by 135
Hybrid Curcumin Compounds: A New Strategy for Cancer Treatment
Teiten, M.-H., Dicato, M. A., & Diederich, M. F. (2014) · Molecules · doi:10.3390/molecules191220839 · Cited by 132
“drugs [7,87,88], hybrid molecules, also called multifunctional or conjugated drugs, are designed by chemical hybridization, wherein two or more drugs having different activities can be co-formulated by connection through a stable or metabolizable linker, allowing simultaneous delivery [6,89,90].”
BackgroundXuan, Y., & Hu, X. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.09.029 · Cited by 123
“Moreover, since combination therapy is a well-established principle of cancer treatment to fight drug-resistant cancers [48–50], the combination of necroptotic inducers with apoptotic inducers would activate more than one death pathways with mechanisms distinct from each other, and thus could more efficiently treat ca…”
BackgroundSalacia root, a unique Ayurvedic medicine, meets multiple targets in diabetes and obesity
Li, Y., Huang, T. H.-W., & Yamahara, J. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.03.005 · Cited by 122
“The other is using two or more active ingredients in one drug (Keith et al., 2005).”
BackgroundHuber, J. L., Donald, R. G. K., Lee, S. H., Jarantow, L. W., Salvatore, M. J., Meng, X., Painter, R. E., Onishi, R., Occi, J., Dorso, K., et al. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.05.012 · Cited by 121
Biological screening of natural products and drug innovation in China
Wang, M., Hao, X., & Chen, K. (2007) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2007.2036 · Cited by 130
“The foundation of various clinical efficacies observed in patients is believed to rely on numerous interacting combinations of natural products (Keith et al. 2005).”
BackgroundPredictive approaches for drug combination discovery in cancer
Madani Tonekaboni, S. A., Soltan Ghoraie, L., Manem, V. S. K., & Haibe-Kains, B. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bbw104 · Cited by 115
Lee, M. S., Johansen, L., Zhang, Y., Wilson, A., Keegan, M., Avery, W., Elliott, P., Borisy, A. A., & Keith, C. T. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2235 · Cited by 115
“A systematic approach to searching all possible combinations of drugs can significantly advance this process by revealing both synergies and antagonisms that may be overlooked by the current standard practice of intuition-based combination experiments (12, 13).”
BackgroundSelf-citationCombination therapeutics in complex diseases
He, B., Lu, C., Zheng, G., He, X., Wang, M., Chen, G., Zhang, G., & Lu, A. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12930 · Cited by 112
“In addition to combination therapeutics, one drug might also target multiple functions [19].”
BackgroundRamadass, S. K., Anantharaman, N. V., Subramanian, S., Sivasubramanian, S., & Madhan, B. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.11.005 · Cited by 113
Multifunctional Neuroprotective Derivatives of Rasagiline as Anti-Alzheimer's Disease Drugs
Weinreb, O., Mandel, S. A., Bar‐Am, O., Yogev‐Falach, M., Avramovich‐Tirosh, Y., Amit, T., & Youdim, M. B. H. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.030 · Cited by 121
Rationally Designed Multitarget Agents Against Inflammation and Pain
Hwang, S. H., Wecksler, A. T., Wagner, K. M., & Hammock, B. D. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320130013 · Cited by 122
“Because selectively blocking one of the pathways in the ARA cascade in most cases also causes the production of undesirable or unexpected metabolites, new approaches have been developed to combine therapies to modulate multiple pathway targets simultaneously [135-137].”
BackgroundRecent update on antibacterial and antifungal activity of quinoline scaffolds
Dorababu, A. (2020) · Archiv der Pharmazie · doi:10.1002/ardp.202000232 · Cited by 110
Systems Pharmacology: Defining the Interactions of Drug Combinations
van Hasselt, J. G. C., & Iyengar, R. (2018) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021511 · Cited by 110
Croaker, A., King, G. J. W., Pyne, J. H., Anoopkumar‐Dukie, S., & Liu, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091414 · Cited by 114
“Drug discovery efforts have recently broadened to include multicomponent drug regimens acting in concert on multiple targets [26].”
BackgroundSuccess stories of natural product-based hybrid molecules for multi-factorial diseases
Choudhary, S., Singh, P. K., Verma, H., Singh, H., & Silakari, O. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.057 · Cited by 109
Farha, M. A., Czarny, T. L., Myers, C. L., Worrall, L. J., French, S., Conrady, D. G., Wang, Y., Oldfield, E., Strynadka, N. C. J., & Brown, E. D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511751112 · Cited by 104
“Further, synergistic drug combinations are now essential therapeutic strategies in the clinic in areas such as cancer, HIV, and infectious diseases (8).”
BackgroundDiscovery of Mdm2-MdmX E3 Ligase Inhibitors Using a Cell-Based Ubiquitination Assay
Herman, A. G., Hayano, M., Poyurovsky, M. V., Shimada, K., Skouta, R., Prives, C., & Stockwell, B. R. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0104 · Cited by 100
“Bliss independence was determined by the formula C=A+B-A*B, where A is the treatment with one compound alone and B is treatment with the second compound alone (34).”
Self-citationProtein Dynamics in Drug Combinations: a Linear Superposition of Individual-Drug Responses
Geva‐Zatorsky, N., Dekel, E., Cohen, A., Danon, T., Cohen, L., & Alon, U. S. (2010) · Cell · doi:10.1016/j.cell.2010.02.011 · Cited by 111
“Drug combinations are thought to be essential to treat multifactor diseases (Berenbaum, 1989; Greco et al., 1995; Keith et al., 2005).”
BackgroundInfluentialMa, Y., Liu, D., Wang, D., Wang, Y., Fu, Q., Fallon, J. K., Yang, X., He, Z., & Liu, F. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400778r · Cited by 100
Fallahi‐Sichani, M., Moerke, N. J., Niepel, M., Zhang, T., Gray, N. S., & Sorger, P. K. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145877 · Cited by 99
“According to this model, the excess above the predicted Bliss independence represents the synergistic effect of the combination treatment (Keith et al, 2005).”
Jin, Y., Qu, C., Tang, Y., Pang, H., Liu, L., Zhu, Z., Shang, E., Huang, S., Sun, D., & Duan, J. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.01.033 · Cited by 99
Wang, T., Liu, X.-H., Guan, J., Ge, S., Wu, M.-B., Lin, J.-P., & Yang, L.-R. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.076 · Cited by 93
How to escape the cancer attractor: Rationale and limitations of multi-target drugs
Huang, S., & Kauffman, S. A. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.06.003 · Cited by 118
“in drug discovery [5, 6] have led to a new climate of multi-dimensional mechanistic reasoning.”
BackgroundLong, F., Yang, H. Q., Xu, Y., Hao, H., & Li, P. (2015) · Scientific Reports · doi:10.1038/srep12361 · Cited by 106
“1): (1) the identification of BECCs via a bioactive equivalence oriented feedback screening approach; (2) screening active compounds based on chemical family classification; (3) determining the pharmacological activity of individual compounds and their interactive mode; (4) designation of dominant compounds combinatio…”
Lin, H., Jin, D., Freitag, T. E., Sun, W., Yu, Q., Fu, J., & Ma, J. (2016) · Environmental Pollution · doi:10.1016/j.envpol.2016.02.043 · Cited by 97
The influence of traditional herbal formulas on cytokine activity
Burns, J. J., Zhao, L., Taylor, E. W., & Spelman, K. (2009) · Toxicology · doi:10.1016/j.tox.2009.09.020 · Cited by 109
“Recent research into cellular networks demonstrates that pharmacological agents that provide multiple signals can impact the complex equilibrium of whole cellular networksmore favorably than drugs that act on a single target (Ágoston et al., 2005; Briskin, 2000; Csermely, 2004; Csermely et al., 2005; Keith et al., 200…”
BackgroundMethods and Applications of Structure Based Pharmacophores in Drug Discovery
Pirhadi, S., Shiri, F., & Ghasemi, J. B. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611313090006 · Cited by 96
“The advantages of multitarget drugs ,applied at limited multiple targets, are [95,96] improvement of therapeutic efficacies, enhancement of safety profiles, and reduction of resistance activities by simultaneously modulating the activity of a primary therapeutic target and the counteractive elements and resistance act…”
BackgroundTinnitus: network pathophysiology-network pharmacology
Elgoyhen, A. B., Langguth, B., Vanneste, S., & De Ridder, D. (2012) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2012.00001 · Cited by 96
“However, these problems can be reduced with polypharmacology, since it allows combination therapies at lower doses, resulting in higher efficacy and/or reduced side-effects compared to monotherapies (Morphy et al., 2004; Keith et al., 2005).”
BackgroundThe use of multi-target drugs in the treatment of neurodegenerative diseases
der Schyf, C. J. V. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.13 · Cited by 103
Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities
Barbosa, E. J., Löbenberg, R., de Araújo, G. L. B., & Bou‐Chacra, N. A. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.05.004 · Cited by 98
Adeniji, O. O., Nontongana, N., Okoh, J. C., & Okoh, A. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315038 · Cited by 101
Hahn, C. K., Ross, K. N., Warrington, I. M., Mazitschek, R., Kanegai, C. M., Wright, R. D., Kung, A. L., Golub, T. R., & Stegmaier, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710413105 · Cited by 91
“Gene expression was evaluated with Affymetrix U133A DNA microarrays (see SI Materials and Methods for full details).”
BackgroundInfluentialA global view of drug-therapy interactions
Nacher, J. C., & Schwartz, J. (2008) · BMC Pharmacology · doi:10.1186/1471-2210-8-5 · Cited by 102
“Therefore, multi-target drug design combined with a networkdependent approach [11] create a promising concept to combat diseases based on multi-genetic disorders such as cancer, and diseases that involve a variety of cell types such as immunoinflamatory disorders and diabetes [33].”
BackgroundSuppressive drug combinations and their potential to combat antibiotic resistance
Singh, N. P., & Yeh, P. J. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2017.102 · Cited by 107
High‐order combination effects and biological robustness
Lehár, J., Krueger, A., Zimmermann, G., & Borisy, A. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.51 · Cited by 95
“Combinations are also very effective in biological experiments (Sharom et al , 2004; Keith et al , 2005).”
Self-citationDrug–drug interaction prediction: databases, web servers and computational models
Zhao, Y. F., Yin, J., Zhang, L., Zhang, Y., & Chen, X. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad445 · Cited by 110
“For instance, the combination therapy of doxorubicin, cyclophosphamide, vincristine and prednisone is commonly implemented in cancer chemotherapy regimens [10, 11].”
BackgroundBar‐Am, O., Amit, T., Kupershmidt, L., Aluf, Y., Mechlovich, D., Kabha, H., Danovich, L., Zurawski, V. R., Youdim, M. B. H., & Weinreb, O. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.10.026 · Cited by 94
Ndhlala, A. R., Stafford, G. I., Finnie, J. F., & Staden, J. V. (2011) · South African Journal of Botany · doi:10.1016/j.sajb.2011.09.002 · Cited by 99
“Herbal mixtures containing multiple and complex compounds can thus offer a solution to multi-drug resistance that is evidenced in most antibiotics, antimalarial, antiviral and anticancer treatments (Keith et al., 2005; Yeh and Kishony, 2007).”
BackgroundSystematic discovery of drug interaction mechanisms
Chevereau, G., & Bollenbach, T. (2015) · Molecular Systems Biology · doi:10.15252/msb.20156098 · Cited by 88
“When drugs are combined, interactions like synergism and antagonism can occur (Loewe, 1928; Keith et al , 2005) (Fig 1A); such drug interactions are often critical for the success of multidrug treatments (Pillai et al , 2005) and can slow or accelerate antibiotic resistance evolution (Chait et al ,…”
Shi, J., Cao, B., Wang, X., Aa, J., Duan, J., Zhu, X., Wang, G., & Liu, C. (2015) · Journal of Chromatography B · doi:10.1016/j.jchromb.2015.10.014 · Cited by 92
Multifunctional drugs with different CNS targets for neuropsychiatric disorders
Van der Schyf, C. J., Geldenhuys, W. J., & Youdim, M. B. H. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04141.x · Cited by 88
Kim, C., Bang, J. H., Kim, Y. E., Lee, S. H., & Kang, J. Y. (2012) · Lab on a Chip · doi:10.1039/c2lc40570a · Cited by 84
Molecular targets of Chinese herbs: a clinical study of hepatoma based on network pharmacology
Gao, L., Wang, X., Niu, Y., Duan, D., Yang, X. L., Hao, J., Zhu, C.-H., Chen, D., Wang, K., Qin, X., et al. (2016) · Scientific Reports · doi:10.1038/srep24944 · Cited by 87
Synthesis, leishmanicidal, trypanocidal and cytotoxic activity of quinoline-hydrazone hybrids
Coa, J. C., Castrillón-L, W., Cardona, W., Cardá, M., Ospina, V., Muñoz, J. A., Vélez, I. D., & Robledo, S. M. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.07.018 · Cited by 87
Network Systems Underlying Traditional Chinese Medicine Syndrome and Herb Formula
Li, S. (2009) · Current Bioinformatics · doi:10.2174/157489309789071129 · Cited by 87
“Correspondingly, there is a tendency of treating complex disease as the operation of perturbed pathways and networks [49].”
BackgroundZhao, F., Li, G., Yang, Y., Shi, L., Xu, L., & Yin, L. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2015.03.035 · Cited by 85
“With the rapid progress of bioinformatics, systems biology and polypharmacology, network-based drug discovery is considered a promising approach toward more cost-effective drug development (Keith et al., 2005; Schadt et al., 2009; Jia et al., 2009; Levinson, 2010).”
MethodAntonello, A., Tarozzi, A., Morroni, F., Cavalli, A., Rosini, M., Hrelia, P., Bolognesi, M. L., & Melchiorre, C. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0608762 · Cited by 85
Activation of the Proapoptotic Bcl-2 Protein Bax by a Small Molecule Induces Tumor Cell Apoptosis
Zhao, G., Zhu, Y., Eno, C. O., Liu, Y., DeLeeuw, L. W., Burlison, J. A., Chaires, J. B., Trent, J. O., & Li, C. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00996-13 · Cited by 92
“Emerging evidence demonstrates that combinations of two or more anticancer drugs are able both to enhance therapeutic effects and to alleviate the side effects of high dosages of single drugs by overcoming the compensatory networks (50, 51).”
BackgroundBanerjee, V., Sharda, N., Huse, J., Singh, D., Sokolov, D., Czinn, S. J., Blanchard, T. G., & Banerjee, A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173919 · Cited by 87
McCormack, E., Haaland, I., Venås, G., Forthun, R. B., Huseby, S., Gausdal, G., Knappskog, S., Micklem, D., Lorens, J. B., Bruserud, Ø., et al. (2011) · Leukemia · doi:10.1038/leu.2011.315 · Cited by 88
A yeast phenomic model for the gene interaction network modulating CFTR-ΔF508 protein biogenesis
Louie, R. J., Guo, J., Rodgers, J. W., White, R., Shah, N. A., Pagant, S., Kim, P., Livstone, M., Dolinski, K., McKinney, B. A., et al. (2012) · Genome Medicine · doi:10.1186/gm404 · Cited by 82
“Many of these regulators are evolutionarily conserved, thus a quantitative systems level model of a gene interaction network model derived from yeast could complement human and animal studies [17].”
BackgroundHerranz‐López, M., Olivares-Vicente, M., Encinar, J. A., Barrajón‐Catalán, E., Segura‐Carretero, A., Joven, J., & Micol, V. (2017) · Nutrients · doi:10.3390/nu9080907 · Cited by 96
Melioidosis: Clinical impact and public health threat in the tropics
Samy, R. P., Stiles, B. G., Sethi, G., & Lim, L. H. K. (2017) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0004738 · Cited by 90
RetractedShi, C., Zhang, Z., Shi, J., Wang, F., & Luan, Y. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.10.009 · Cited by 80
Chemogenomic profiling predicts antifungal synergies
Jansen, G., Lee, A. Y., Epp, E., Fredette, A., Surprenant, J., Harcus, D., Scott, M., Tan, E., Nishimura, T., Whiteway, M., et al. (2009) · Molecular Systems Biology · doi:10.1038/msb.2009.95 · Cited by 80
Chen, J.-B., Chern, T.-R., Wei, T.-T., Chen, C.-C., Lin, J.-H., & Fang, J.-M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400179b · Cited by 74
Block copolymer mixtures as antimicrobial hydrogels for biofilm eradication
Lee, A. L. Z., Ng, V. W. L., Wang, W., Hedrick, J. L., & Yang, Y. Y. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.09.029 · Cited by 76
Huang, L., Jiang, Y., & Chen, Y. (2017) · Scientific Reports · doi:10.1038/srep40752 · Cited by 84
Whittaker, S. R., Cowley, G. S., Wagner, S., Luo, F., Root, D. E., & Garraway, L. A. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0136-t · Cited by 75
“We confirmed that inhibition of MET using crizotinib, SGX523 or foretinib in combination with PLX4720 resulted in nearcomplete inhibition of ERK1/2 phosphorylation and synergistic anti-proliferative activity as determined using the Bliss independence model (Figure S4) (19).”
MethodMartiz, R. M., Patil, S. M., Abdulaziz, M., Babalghith, A. O., Al-Areefi, M. A., Al‐Ghorbani, M., Kumar, J. M., Prasad, A., Nagalingaswamy, N. P. M., & Ramu, R. (2022) · Molecules · doi:10.3390/molecules27082398 · Cited by 79
Systems Biology Brings New Dimensions for Structure-Based Drug Design
Pei, J., Yin, N., Ma, X., & Lai, L. (2014) · Journal of the American Chemical Society · doi:10.1021/ja504810z · Cited by 73
Frequently asked questions in drug combinations and the mass-action law-based answers
Chou, T. (2014) · Synergy · doi:10.1016/j.synres.2014.07.003 · Cited by 79
Antibiotic discovery in the artificial intelligence era
Lluka, T., & Stokes, J. M. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14930 · Cited by 83
“129 As highlighted above, ML may be integrated with systems-level approaches to elucidate dense chemical–genetic networks underlying drug synergy phenotypes.”
BackgroundQu, S., Li, X., Heng, X., Qi, Y., Ge, P., Ni, S., Yao, Z., Guo, R., Yang, N., Cao, Y., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.619288 · Cited by 75
“Development of multi-target therapeutics will help overcome limitations of monotherapies through modulation of multiple cellular pathways (Borisy et al., 2003; Keith et al., 2005).”
BackgroundEfficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis
Kvien, T. K., Fjeld, E., Slatkowsky-Christensen, B., Nichols, M., Zhang, Y., Prøven, A., Mikkelsen, K., Palm, Ø., Borisy, A. A., & Lessem, J. N. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.074401 · Cited by 73
“Synergy is often observed in multi-target therapeutics that modulate the activity of two or more molecular targets to create a novel therapeutic action.(18) 19 In vivo models testing anti-inflammatory combinations containing a low dose steroid have demonstrated a synergistic interaction between the steroid and the enh…”
Self-citationAdditivity of inhibitory effects in multidrug combinations
Russ, D., & Kishony, R. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0252-1 · Cited by 71
Ma, J., Lin, H., Sun, W., Wang, Q., Yu, Q., Zhao, Y., & Fu, J. (2014) · Environmental Science and Pollution Research · doi:10.1007/s11356-014-2685-2 · Cited by 69
“It has been shown in several studies (Chait et al. 2007; Keith et al. 2005) that the coexistence of two or even more antibiotics would present a different effect from when they are acting alone.”
BackgroundChung, S. E., Kim, J., Oh, D. Y., Song, Y., Lee, S. H., Min, S., & Kwon, S. (2014) · Nature Communications · doi:10.1038/ncomms4468 · Cited by 69
Wang, S., Wang, L., Shi, Z., Zhong, Z., Chen, M., & Wang, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097512 · Cited by 73
“The one-dimensional mechanism of action of single-drug chemotherapy often activates and heightens alternative pathways, thereby prompting the emergence of chemoresistance mutations and tumor relapse [39–42].”
BackgroundCheok, C. F., Dey, A., & Lane, D. P. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0161 · Cited by 69
“Although the use of combination drugs/therapy has been described for decades, optimizing the combinations of various drugs at a wide dosage range has only recently been explored on a high-throughput scale (44, 45).”
BackgroundIsgut, M., Mukkavilli, R., Yang, C., Subrahmanyam, V., Rida, P. C. G., & Aneja, R. (2017) · Medicinal Research Reviews · doi:10.1002/med.21444 · Cited by 69
Zhang, C., Xu, G., Liu, Y.-H., Rao, Y., Yu, R., Zhang, Z.-W., Wang, Y., & Liang, T. (2012) · Phytomedicine · doi:10.1016/j.phymed.2012.11.002 · Cited by 69
“However, DM has a multifactorial basis that involves both enetic and environmental risk factors (Keith et al. 2005).”
BackgroundRukhlenko, O. S., Khorsand, F., Krstić, A., Rožanc, J., Alexopoulos, L. G., Rauch, N., Erickson, K. E., Hlavacek, W. S., Posner, R. G., Gómez‐Coca, S., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.06.002 · Cited by 72
“The Bliss independence and Talalay-Chou CI are two separate criteria, and synergy according to one criterion does not mean synergy according to the other (Greco et al., 1995; Keith et al., 2005).”
BackgroundTachykinin receptor antagonists in clinical trials
Quartara, L., Altamura, M., Evangelista, S., & Maggi, C. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903379530 · Cited by 70
Mathematical modeling in cancer drug discovery
Wang, Z., & Deisboeck, T. S. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.06.015 · Cited by 71
Van der Schyf, C. J., Gal, S., Geldenhuys, W. J., & Youdim, M. B. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.8.873 · Cited by 66
“However, a pharmaceutical combination of several drug molecules raises many challenges, not least of which is the associated complexities of combining drug entities that have potentially different degrees of bioavailability, pharmacokinetics and metabolism [8,9].”
BackgroundJoven, J., Rull, A., Rodríguez‐Gallego, E., Camps, J., Riera-Borrull, M., Hernández‐Aguilera, A., Martín-Paredero, V., Segura‐Carretero, A., Micol, V., Alonso‐Villaverde, C., et al. (2012) · Food and Chemical Toxicology · doi:10.1016/j.fct.2012.10.004 · Cited by 71
“However, this may seem a pointless effort because the efficacy of most natural medicines lies in the synergy of diverse components rather than a single compound (Keith et al., 2005).”
BackgroundSribalan, R., Banuppriya, G., Kirubavathi, M., Jayachitra, A., & Padmini, V. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.10.075 · Cited by 67
How Many Drugs Are Catecholics
Yang, D., Ji, H., Tang, G.-Y., Ren, W., & Zhang, H.-Y. (2007) · Molecules · doi:10.3390/12040878 · Cited by 64
“, from “one-drug, one-target” to “onedrug, multiple-targets” [23-27], finding multifunctional antioxidants represents a new trend in antioxidant discovery [28].”
BackgroundJain, A., Sharma, G., Kushwah, V., Thakur, K., Ghoshal, G., Singh, B., Jain, S., Shivhare, U. S., & Katare, O. P. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.01.050 · Cited by 64
Metadata
- Authors
- Keith, C. T., Borisy, A. A., & Stockwell, B. R.
- Affiliations
- Columbia University (US)
- Corresponding author
- Keith, Curtis T.
- Borisy, Alexis A.
- Stockwell, Brent R.
- ORCID
- Stockwell, Brent R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2005-01
- Volume
- 4
- Issue
- 1
- Pages
- 71-78
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1592483428
- Cited by
- 769
- References
- 67
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 30 · 2023: 33 · 2022: 44 · 2021: 36 · 2020: 34 · 2019: 36 · 2018: 42 · 2017: 29 · 2016: 43 · 2015: 51 · 2014: 55 · 2013: 49 · 2012: 47
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Burroughs Wellcome Fund
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Keywords
- combination therapy, systems biology, mechanism of action, drug discovery
- MeSH terms
- Clinical Trials as Topic, Drug Synergism, Drug Therapy, Combination, Humans, Terminology as Topic, Drug Design
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.